N | 384 | 151 | 233 | |
Age at time of GES, mean (SD) | 52.2 (15.9) | 52.2 (14.9) | 52.2 (16.5) | 0.970 |
Duration of GLP-1R agonist use in years, mean (SD) | 1.0 (1.02) | 1.23 (1.34) | 0.86 (0.60) | 0.260 |
Duration of DM, median (IQR) | 8.0 (5.0, 14.0) | 10.0 (5.0, 19.0) | 8.0 (4.0, 10.0) | 0.033 |
HbA1C, median (IQR) | 8.1 (6.8, 9.7) | 8.1 (6.9, 9.7) | 8.1 (6.7, 9.7) | 0.960 |
Gender | | | | 0.071 |
Male | 97 (25.26%) | 46 (30.46%) | 51 (21.89%) | |
Female | 287 (74.74%) | 105 (69.54%) | 182 (78.11%) | |
Ethnicity | | | | 0.500 |
Non-Hispanic | 70 (18.23%) | 30 (19.87%) | 40 (17.17%) | |
Hispanic | 314 (81.77%) | 121 (80.13%) | 193 (82.83%) | |
GES results | | | | --- |
Delayed GE | 151 (39.32%) | --- | --- | |
Normal GE | 233 (60.68%) | --- | --- | |
GLP-1R agonist use | | | | 0.130 |
No | 332 (86.68%) | 126 (83.44%) | 206 (88.79%) | |
Yes | 51 (13.32%) | 25 (16.56%) | 26 (11.21%) | |
DM (Y/N) | | | | <0.001 |
N | 157 (42.55%) | 45 (30.20%) | 112 (50.91%) | |
Y | 212 (57.45%) | 104 (69.80%) | 108 (49.09%) | |
Smoking hx | | | | 0.430 |
No | 299 (79.95%) | 116 (77.85%) | 183 (81.33%) | |
Yes | 75 (20.05%) | 33 (22.15%) | 42 (18.67%) | |
Alcohol use | | | | 0.630 |
No | 356 (95.19%) | 143 (95.97%) | 213 (94.67%) | |
Yes | 18 (4.81%) | 6 (4.03%) | 12 (5.33%) | |